Mum-of-five 'begged for help' before hospital death
A care worker "begged and pleaded" for help before dying shortly after childbirth, her mother said.
Laura-Jane Seaman, 36, told staff she could feel bleeding after delivering her fifth child at Broomfield Hospital in Chelmsford, Essex, in December 2022.
Her mum, Sarah Shead, supports a national inquiry, and said of her daughter: "She told them she was dying and no-one took her seriously until it was too late and the damage was done."
Broomfield's, chief executive, Matthew Hopkins said care was an "absolute priority" after Health Secretary Wes Streeting announced a national inquiry into maternity services.
The final list of trusts involved was not revealed in Monday's announcement.
However, the BBC was told bosses at the Mid and South Essex NHS Foundation Trust (MSE) would meet with government officials as part of the investigation.
A coroner in Auguest 2024 ruled multiple failures by staff amounted to "neglect" and led to Ms Seaman's death two days after giving birth at the MSE-run hospital.
The mother-of-five, from Witham, Essex had repeatedly warned of feeling dizzy and numb, alongside an internal "gushing".
"She begged for her life, she begged me for her life and I thought they were doing everything they could do," Ms Shead told the BBC.
"I will forever live with the fact that I didn't shout and scream and say 'What are you doing?', because they appeared to be doing everything.
"But what we were seeing was not what was actually happening."
Ms Seaman had been known to MSE officials to be at high risk of heavy bleeding post-birth.
She was able to breastfeed her newborn before her condition deteriorated, later suffering a significant peritoneal haemorrhage that proved fatal.
"I'm the mother that lost a daughter who was fit, well and had a 99.9% of surviving had they realised her spleen had ruptured earlier," Ms Shead added.
She said the national inquiry, due to begin this summer and report back by December, was overdue.
"I think this is the only way for the health service to learn where it needs to improve," Ms Shead explained.
"There are too many deaths, too many losses. My hope is this happens quickly."
Maternity care at Broomfield Hospital was rated "inadequate" by the Care Quality Commission (CQC) in January.
Mr Hopkins said he was overseeing an action plan to improve the safety of its care.
"The care and safety of families using our maternity and neonatal services is an absolute priority," he continued.
"We will support any work to tackle health inequalities and improve maternity services for families across the country."
Follow Essex news on BBC Sounds, Facebook, Instagram and X.
National inquiry announced after maternity failings
Mum dies after hospital's 'basic failures' - report
Mother died after neglect by hospital - coroner
Mid and South Essex NHS Foundation Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
World's most deadly viruses to be held at new lab in Surrey
Cutting-edge laboratories to hold and study the world's most deadly diseases are to be built in Surrey. Fatal and incurable viruses will be researched at a new facility in Weybridge to help prevent future pandemics and also to prepare for a potential terror attack with a biological weapon. The new National Biosecurity Centre will have the highest classification of lab biosecurity to analyse the most dangerous diseases, known as biosafety level four pathogens, which include Ebola. This upgrade in biosecurity at Weybridge puts it on equivalent footing to the UK Healthy Security Agency (UKHSA) base at Porton Down, but on a much bigger scale, as it will test and study infected farm animals, not just rodents. The Department for Environment, Food and Rural Affairs (Defra) on Monday announced £1 billion of taxpayer money to fund the centre, as part of a £2.8 billion overhaul of the Government's marquee animal disease site. The level four labs will allow staff to safely handle deadly diseases by working in self-contained suits with a dedicated air supply, air locks upon entry and exit, negative air pressure, airtight facilities, and chemical disinfection showers. Scientists will use the new facilities, due to open in 2033, to prevent outbreaks of disease. This includes known pathogens, but also as yet unknown future outbreaks such as 'Disease X', a hypothetical pathogen that will cause the next pandemic, officials say. Environment Secretary Steve Reed told The Telegraph: 'Covid happened once and it can happen again, so we need to invest in the world-class facilities we need to keep not just the economy safe, but the people in this country safe. 'This will be one of only five or six facilities in the world up to this standard. Somebody described this national biosecurity centre to me as being the MI5 of animal and plant disease.' It will also allow the centre to lead on anti-bioterrorism work to ensure that diseases of plants or animals are not weaponised against Britain. The National Biosecurity Centre will work alongside scientists at the MoD's Defence Science and Technology Laboratory and the UKHSA facilities at Porton Down. This three-pronged network will form the backbone of the tranche of the UK's National Security Strategy against biological agents, both zoonotic and from hostile states. Around 60 per cent of all diseases are zoonotic and spread to humans via animals. Mr Reed said: 'In the same way pathogens can be used against humans, they can be used against the plants and animals we depend on for food. 'This site will be part of a network of facilities we need to strengthen national security. This is where bioweapon work will be researched and tackled so that we can recognise it, should it happen, and then have the means to combat it.' The Weybridge site is the main research centre of the Animal and Plant Health Agency (APHA) and has been criticised for being in poor condition. Scientists at these labs lead the response to bird flu, foot-and-mouth disease, and bluetongue. It is also where swabs from the recent rabies fatality were tested. Mr Reed added: 'The money is so desperately needed. You can see just from looking around that these are very old facilities – some remind me of my old science lab at school. 'It shouldn't look like that, it should be a world-class facility. It has world-class people working in it, but the buildings and the tools are not up to the standard they need to be. The previous Government let them become close to obsolete. 'This investment is desperately needed now to protect food production, farming and the economy as well as human beings.' A 2022 National Audit Office report found the site to be in shoddy shape, with it having the highest possible risk of failure possible, and warned it would be unable to cope with a serious outbreak. Dr Jenny Stewart, APHA Senior Science Director, told The Telegraph: 'The new centre will add some new capabilities that will let us deal with diseases that we can't currently deal with on this site, and allow us to do research. 'That will mean that we're ready for the next thing that comes. We have a thing called 'Pathogen X', or 'Disease X', and at this site we can be ready for whatever that might be. 'The step change is that we're going to have a higher level of containment on the site that lets us deal with more dangerous diseases than we currently manage on this site. 'We keep saying we are a Reliant Robin, and we are getting a spacecraft.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
New York Times
an hour ago
- New York Times
The C.D.C.'s Vaccine Meeting: What to Watch For
Some new members of the C.D.C.'s Advisory Committee on Immunization Practices, handpicked by health secretary Robert F. Kennedy Jr., have expressed deep skepticism of vaccines. One of them, Robert Malone, said on X that he considers the label 'anti-vaxer' to be 'high praise.' Mr. Kennedy named Dr. Malone a co-chair of the committee on Tuesday. The panel's agenda on Wednesday includes some topics that are closely associated with the anti-vaccine movement and omits several others that were originally scheduled for discussion. Here's what to watch for. The panelists: Most of the seven new committee members are not vaccine experts, and a few have not publicly expressed their views on childhood immunizations. The meeting should offer clues about their opinions on the safety of various vaccines. Thimerosal: A perennial target of the anti-vaccine movement, and of Mr. Kennedy, thimerosal is a mercury-based preservative that was falsely said to be a cause of autism. Most childhood vaccines in the United States have not contained thimerosal since 2001, even as autism rates have continued to rise. Flu vaccine: The panelists are scheduled to vote on the only pediatric formulation that contains thimerosal, a multidose vial of the flu shot, which uses it to prevent microbial contamination. That formulation accounts for a small fraction of flu vaccines administered to Americans. In a twist, Lyn Redwood, a former leader of Children's Health Defense, the anti-vaccine group founded by Mr. Kennedy, is scheduled to present recommendations for the vaccine. M.M.R.V. vaccine: This combination vaccine for measles, mumps, rubella and chickenpox is on the agenda under 'proposed recommendations' regarding its use in children younger than 4. It slightly increases the risk of febrile seizures, which can occur with any childhood illness but do not cause lasting harm. The C.D.C. already recommends administering the M.M.R. shot and the chickenpox shot separately in the first dose. Maternal and pediatric vaccines for respiratory syncytial virus: It may turn out to be a straightforward vote on recommending clesrovimab, a new monoclonal antibody approved by the Food and Drug Administration earlier this month, as an alternative to protect infants. But a scheduled update on the safety of the maternal vaccine opens the door to restrictions. The presenters: A dozen or more C.D.C. scientists typically present data to the panelists. This time, only a few senior scientists are scheduled to present most of the data.
Associated Press
2 hours ago
- Associated Press
ThinkSono Secures Additional £4.5M / $6Mn Funding, Expands Team and Operations Across the UK, EU and U.S.
LONDON, GB / ACCESS Newswire / June 25, 2025 / ThinkSono, a pioneering ultrasound AI company, has built the world's first software for DVT (blood clot) detection. For context, DVT is a leading cause of morbidity and mortality worldwide, and up to 900,000 people in the U.S are affected by DVT each year [1]. The company has successfully completed its second oversubscribed seed funding round, securing an additional £4.5Mn ($6Mn / €5.4Mn). It has raised £9.6Mn ($13Mn / €11.3Mn) to date. The latest round is led by id4 ventures, and joined by Brandenburg Kapital, Cur8 Capital and several key opinion leaders (KOLs) in vascular surgery. The company founders also participated in the funding round in alignment with other investors. Momentum & Milestones: This significant investment builds upon the regulatory, clinical, and commercial momentum the company has already achieved since raising £2.1Mn ($2.8Mn / €2.5Mn) in 2024. It obtained the world's first Class IIb CE mark for AI software to detect DVT. The new funding has enabled the company to increase its team size and fill key positions, including a CFO, Sales Director, Chief Compliance Officer, UK Medical Director, and expand its medical advisory board. In addition, the company has expanded its U.S. operations with key staff and is progressing with multi-centred clinical trials for subsequent FDA filing for its ThinkSono Guidance software. Prominent U.S. Hospitals, including NYU Langone Health, Allegheny Health Network (AHN), Temple Health, and UW Health University Hospital, have been selected as key sites. Finally, the company has published a peer-reviewed paper in npj Digital Medicine that shows excellent clinical and health economic results. Due to its importance, this study has also been highlighted in npj Digital Medicine as an Editorial. This achievement underscores the company's commitment to delivering cutting-edge AI solutions that meet rigorous quality and safety standards, positioning ThinkSono as a leader in the field of AI ultrasound guidance. ThinkSono has partnered with hospitals across the U.S. and Europe, including the UK, Germany, Greece and Poland. Comments from CEO and KOLs: Fouad Al Noor, CEO and Co-founder of ThinkSono: 'This funding shows that leading investors are doubling down on ThinkSono, and our confidence is further reinforced by having clinical KOLs investing alongside our investors. We're also very pleased to have an extremely competent team that will be supporting our UK/EU commercialisation efforts as well as our U.S. FDA clearance process' Michael Blaivas, Professor of Emergency Medicine, and ThinkSono's Chief Medical Officer: 'The inability to quickly and timely rule out lower extremity DVT has been the bane of healthcare providers for decades. This problem impacts settings from office practices, clinics, emergency departments, hospital floors to intensive care units and more. ThinkSono's technology addresses this problem directly and has the potential to significantly improve patient care across Europe and beyond.' Glenn Jacobowitz, ThinkSono Clinical Advisor, Professor of Vascular Surgery and the Director of Ambulatory Vascular Surgery, Western Region at Northwell Health: 'The ThinkSono Guidance System would be a powerful tool in our diagnostic arsenal. It's the kind of innovation that can literally change the way high-quality, efficient care is delivered to patients on a daily basis. The potential impact in the US and abroad is enormous.' Dr Satish Muluk, director of vascular surgery at Allegheny Health Network: 'This breakthrough technology has the potential to dramatically improve patient outcomes by accelerating DVT detection and subsequent care. By empowering a wider range of healthcare professionals to perform this imaging procedure, we can reach patients more quickly and minimize delays in lifesaving treatment.' 'The fact that ThinkSono's technology can be used by a variety of healthcare staff, instead of only sonogram-trained technicians, is a significant benefit amid the ongoing healthcare workforce shortage, which includes ultrasound technicians and qualified sonographers' [2] About ThinkSono: ThinkSono is a leading ultrasound AI technology company specialising in ultrasound guidance solutions. Its software has been peer reviewed in multiple studies across more than 10 hospitals and with more than 1,000 patients scanned in trials across the UK, Germany, Greece and the U.S. Its technology is clinically validated with strong peer-reviewed health economics. Contact: [email protected] Regulatory information The EU (MDR) Class IIb Intended Purpose of ThinkSono Guidance is found here: Research: All published research found here: References: [1] [2] AHN Press release: Note: ThinkSono Guidance is not FDA cleared and will not be available in the U.S. until full clearance is given. Please contact [email protected] for more information. Approximate conversion from GBP to USD and EUR based on 24 Jun, 15:22 UTC from Morningstar Contact Information Fouad Noor CEO [email protected] SOURCE: ThinkSono Ltd press release
